Mustang Bio Inc (MBIO) Stock Price, Quote & News

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 201...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.mustangbio.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

HJAC Nov. 14 at 4:22 PM

$MBIO Does anyone realize that FBIO also includes MBIO? Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

0 · Reply

Invest2live Nov. 12 at 9:15 PM

$EXPE 145% already; congrats 🎊 🎉🎈 Follow for more research-based stocks alerts. Checkout $TTD and $MBIO

0 · Reply

Invest2live Nov. 12 at 8:53 PM

$CYPH 379% already; congrats 🎉 🎊🎈 Follow for more research-based stocks alerts. Checkout $MBIO and $BBAI

0 · Reply

NextRunnerTV Nov. 12 at 3:05 AM

$MBIO

0 · Reply

NextRunnerTV Nov. 12 at 2:51 AM

$MBIO $XAIR $AMZE $TRUG https://www.tiktok.com/@nextrunnertv/video/7571665460014451981

0 · Reply

YGLD Nov. 9 at 9:50 PM

🎲 🎲 $BKYI $GNPX $MBIO $MSPR $RUBI

0 · Reply

YGLD Nov. 9 at 9:10 PM

Thats Like All Of Fintwit 😂 $BKYI $GNPX $MBIO $MSPR $RUBI

0 · Reply

SMM82 Nov. 9 at 2:15 PM

$MBIO Two takeaways from Friday's 10-Q 1) MB-106 program update... ouch

1 · Reply

YGLD Nov. 7 at 10:23 PM

Killer Moves We’ve Seen Just In The Past Few Days 📈 Falls Trading Is Here 🍂 💸 $BKYI $RUBI $MSPR $GNPX $MBIO

0 · Reply

ConnieOwen145 Nov. 7 at 4:34 PM

$MBIO trades sideways as biotech and AI stocks find balance. AITX expands adoption through integrated automation, optimizing cost and performance.

0 · Reply

Dow Dips 1%; Mustang Bio Shares Spike Higher

Jul 7, 2025, 8:30 AM EDT - 4 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mar 5, 2025, 4:15 PM EST - 9 months ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

Feb 27, 2025, 4:05 PM EST - 9 months ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Feb 11, 2025, 4:10 PM EST - 9 months ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2025, 8:00 AM EST - 9 months ago

Mustang Bio Announces Closing of $8 Million Public Offering

Feb 6, 2025, 7:00 AM EST - 10 months ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Jan 14, 2025, 8:00 AM EST - 10 months ago

Mustang Bio Announces Reverse Stock Split

Nov 12, 2024, 8:30 AM EST - 1 year ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Nov 7, 2024, 8:30 AM EST - 1 year ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Oct 24, 2024, 2:10 PM EDT - 1 year ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Jun 21, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2024, 2:52 AM EDT - 1 year ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 17, 2024, 9:21 AM EDT - 1 year ago

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

May 2, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 1 year ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Mar 28, 2024, 9:00 AM EDT - 1 year ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 7, 2024, 7:30 AM EST - 1 year ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Jan 11, 2024, 8:30 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Dec 11, 2023, 8:30 AM EST - 2 years ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Nov 14, 2023, 4:05 PM EST - 2 years ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:28 AM EDT - 2 years ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2023, 2:15 PM EDT - 2 years ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 2 years ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Sep 7, 2023, 8:15 AM EDT - 2 years ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Aug 16, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Jul 31, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jun 15, 2023, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

May 18, 2023, 8:03 AM EDT - 2 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 12, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 11, 2023, 4:03 PM EDT - 2 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Mar 29, 2023, 4:15 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Jan 17, 2023, 8:15 AM EST - 3 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Dec 19, 2022, 8:30 AM EST - 3 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Nov 14, 2022, 4:05 PM EST - 3 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Oct 27, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 6, 2022, 8:30 AM EDT - 3 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Sep 23, 2022, 4:55 PM EDT - 3 years ago

Mustang Bio: This Horse May Gallop Still

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

HJAC Nov. 14 at 4:22 PM

0 · Reply

Invest2live Nov. 12 at 9:15 PM

$EXPE 145% already; congrats 🎊 🎉🎈 Follow for more research-based stocks alerts. Checkout $TTD and $MBIO

0 · Reply

Invest2live Nov. 12 at 8:53 PM

$CYPH 379% already; congrats 🎉 🎊🎈 Follow for more research-based stocks alerts. Checkout $MBIO and $BBAI

0 · Reply

NextRunnerTV Nov. 12 at 3:05 AM

$MBIO

0 · Reply

NextRunnerTV Nov. 12 at 2:51 AM

$MBIO $XAIR $AMZE $TRUG https://www.tiktok.com/@nextrunnertv/video/7571665460014451981

0 · Reply

YGLD Nov. 9 at 9:50 PM

🎲 🎲 $BKYI $GNPX $MBIO $MSPR $RUBI

0 · Reply

YGLD Nov. 9 at 9:10 PM

Thats Like All Of Fintwit 😂 $BKYI $GNPX $MBIO $MSPR $RUBI

0 · Reply

SMM82 Nov. 9 at 2:15 PM

$MBIO Two takeaways from Friday's 10-Q 1) MB-106 program update... ouch

1 · Reply

YGLD Nov. 7 at 10:23 PM

Killer Moves We’ve Seen Just In The Past Few Days 📈 Falls Trading Is Here 🍂 💸 $BKYI $RUBI $MSPR $GNPX $MBIO

0 · Reply

ConnieOwen145 Nov. 7 at 4:34 PM

$MBIO trades sideways as biotech and AI stocks find balance. AITX expands adoption through integrated automation, optimizing cost and performance.

0 · Reply

SMM82 Nov. 4 at 7:37 PM

$MBIO Feels like HC Wainwright dilution with some of the bid/ask orders...

2 · Reply

wilosmiles Nov. 3 at 6:18 PM

$MBIO hmmm cheap but no volume

1 · Reply

Invest2live Nov. 3 at 4:24 PM

$LCTX 60% already; congrats 🌿🎈🎉 Check out $FORA and $MBIO

0 · Reply

Invest2live Oct. 31 at 3:23 PM

$MBIO now again in buy zone; do your DD and get in. This has growth stability now and in fairly good financial health.

0 · Reply

SMM82 Oct. 23 at 2:34 AM

$MBIO Not looking good here. Thought it might get some retrace of that spike 3 months ago, but doesn’t seem to have the juice. ahhh well…

0 · Reply

LesleyMoore494 Oct. 21 at 4:51 PM

$MBIO transforming biotech; AITX transforming industries — profits achieved, momentum growing, and AI leading the narrative.

0 · Reply

AmySharp603 Oct. 17 at 3:42 PM

$MBIO engineering therapies, AITX engineering the future — construction and healthcare clients now rely on its growing ecosystem.

0 · Reply

POD72225_GTSR3249 Oct. 16 at 6:44 PM

$MBIO Looks like another PILE!!!

0 · Reply

SMM82 Oct. 16 at 2:46 PM

$MBIO Stronger volume today but large spreads... see what direction it takes. Bid at $1.60 / ask at $1.67 as i write this...

1 · Reply

ErockTrades Oct. 16 at 1:20 PM

$MBIO Parabolic watch set up, way under radar

0 · Reply

Invest2live Oct. 15 at 5:56 PM

$ABSI 83% already; congrats 🎉 🎈🎊 Checkout $IBIO and $MBIO; both had dark past but now looks promising

0 · Reply

SMM82 Oct. 15 at 2:17 PM

$MBIO Break through this $1.70 and should see a fairly quick move up to ~$1.85 before next set of resistance. Over $1.85 and she's got some room to run. Bullish in the short-term

0 · Reply

Market Cap	9.05M
Revenue (ttm)	0.00
Net Income (ttm)	-15.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	89,600
Avg Vol	113,470
Day's Range	N/A - N/A
Shares Out	7.24M
Stochastic %K	17%
Beta	2.30
Analysts	Strong Buy
Price Target	$8.00